Jackie Walling, MBChB, PhD, is a British trained physician scientist and the principal of a consulting group that provides expertise on a wide range of global drug development and regulatory projects in oncology and rare diseases. Her leadership has directly impacted the successful development and regulatory approval of several medicines including gemcitabine, pemetrexed, elosulfase, relugolix and talazoparib. Dr. Walling received an MBChB from the University of Bristol and BSc and PhD degrees from the University of Southampton, UK.
Jeff Judson has a cross-cutting responsibility at Aminex in investor recruitment, regulatory oversight, communications, and project management. His career spans 35 years of working on Capitol Hill, studying and influencing public and regulatory policy at all levels of government as a think tank president and later assisting corporations and trade associations to overcome regulatory obstacles.
Dr. Burns is the scientific founder of Aminex. Mark earned a PhD at the University of Michigan and post-doctoral training in bio-organic chemistry at Rice University. During his over 20 years of experience in biotechnology Mark led the discovery efforts resulting in Aminex’s AMXT 1501/DFMO assets. Mark has obtained 15 U.S. Patents and published 21 scientific papers. He has extensive experience in the fields of medicinal, combinatorial, enzyme inhibitor design, analytical and process chemistry.